EP4615398A1

EP4615398A1 - A personal care composition

Info

Publication number: EP4615398A1
Application number: EP23790590.6A
Authority: EP
Inventors: Xuelan GU; Tingyan MI
Original assignee: Unilever Global IP Ltd; Unilever IP Holdings BV
Current assignee: Unilever Global IP Ltd; Unilever IP Holdings BV
Priority date: 2022-11-11
Filing date: 2023-10-16
Publication date: 2025-09-17
Also published as: JP2025535577A; WO2024099689A1; MX2025005283A; CN120187400A

Abstract

Disclosed is a personal care comprising carboxymethyl cysteine compound and resorcinol derivative.

Description

A PERSONAL CARE COMPOSITION

Field of the Invention

The present invention relates to a personal care composition comprising carboxymethyl cysteine compound and resorcinol derivative. It was surprisingly found that the expression of TXNRD1 gene is synergistically elevated by combining carboxymethyl cysteine compound with resorcinol derivative.

Background of the Invention

Human skin may provide physicochemical protection against environmental insults through its barrier function, mechanical strength and imperviousness to water. It is constantly exposed to harmful environments and extreme conditions, such as ultra-violet radiation, blue light, pollution etc. Such harmful environmental applications may cause excessive generation of reactive oxygen species (ROS) thereby resulting in an oxidative stress condition. Oxidative stress may affect our skin in many ways including signs of premature aging such as wrinkles, fine lines, uneven skin tone.

Thioredoxin reductase 1 (TXNRD1) is an oxidoreductase encoded by the TXNRD1 gene in humans and a member of the antioxidant thioredoxin system. TXNRD1 plays an important role in oxidative stress control. It reduces and activates thioredoxin, an oxidoreductase containing a dithiol-disulfide active site. Thioredoxin binds ROS before they can harm cells and thus protects cells against oxidative stress.

The present inventors have recognized there is a need to develop a personal care composition which is capable of improving the gene expression of TXNRD1. Therefore, the present inventors have developed a personal care composition comprising carboxymethyl cysteine compound and resorcinol derivative. It was surprisingly found that by combining carboxymethyl cysteine compound with resorcinol derivative, the expression of TXNRD1 gene is synergistically elevated.

Summary of the Invention

In a first aspect, the present invention is directed to a personal care composition comprising carboxymethyl cysteine compound and resorcinol derivative.

In a second aspect, the present invention is directed to a method for providing antioxidation, and/or anti-aging benefit; reducing oxidative stress; and/or upregulating the expression of thioredoxin reductase 1 gene, comprising a step of topically applying to the skin the composition of the present invention.

In a third aspect, the present invention is directed to use of the composition of the present invention for providing antioxidation, and/or anti-aging benefit; reducing oxidative stress; and/or upregulating the expression of thioredoxin reductase 1 gene.

All other aspects of the present invention will more readily become apparent upon considering the detailed description and examples which follow.

Detailed Description of the Invention

Except in the examples, or where otherwise explicitly indicated, all numbers in this description indicating amounts of material or conditions of reaction, physical properties of materials and/or use may optionally be understood as modified by the word “about”.

All amounts are by weight of the composition, unless otherwise specified.

It should be noted that in specifying any range of values, any particular upper value can be associated with any particular lower value.

For the avoidance of doubt, the word “comprising” is intended to mean “including” but not necessarily “consisting of’ or “composed of’. In other words, the listed steps or options need not be exhaustive.

The disclosure of the invention as found herein is to be considered to cover all embodiments as found in the claims as being multiply dependent upon each other irrespective of the fact that claims may be found without multiple dependency or redundancy.

Where a feature is disclosed with respect to a particular aspect of the invention (for example a composition of the invention), such disclosure is also to be considered to apply to any other aspect of the invention (for example a method of the invention) mutatis mutandis.

The carboxymethyl cysteine compound refers to compound selected from carboxymethyl cysteine, salt of carboxymethyl cysteine, ester of carboxymethyl cysteine, amide of carboxymethyl cysteine or a mixture thereof. Preferably, the carboxymethyl cysteine compound comprises carboxymethyl cysteine, ester of carboxymethyl cysteine, and/or salt of carboxymethyl cysteine. More preferably, the carboxymethyl cysteine compound comprises carboxymethyl cysteine, and/or salt of carboxymethyl cysteine. Even more preferably, carboxymethyl cysteine compound comprises salt of carboxymethyl cysteine. Still even more preferably the carboxymethyl cysteine compound comprises lysine carboxymethyl cysteinate and most preferably, the carboxymethyl cysteine compound is lysine carboxymethyl cysteinate.

Preferably, the carboxymethyl cysteine compound is present in amount of at least 0.00001%, more preferably at least 0.0001 %, even more preferably at least 0.001 %, still even more preferably at least 0.01%, and most preferably at least 0.1 % by weight of the composition. Preferably, the carboxymethyl cysteine compound is present in amount of no greater than 10%, more preferably no greater than 5%, even more preferably no greater than 3%, still even more preferably no greater than 1 %, and most preferably no greater than 0.5% by weight of the composition.

Preferably, the lysine carboxymethyl cysteinate is present in amount of no greater than 10%, more preferably no greater than 5%, even more preferably no greater than 3%, still even more preferably no greater than 1 %, and most preferably no greater than 0.5% by weight of the composition. Preferably, the lysine carboxymethyl cysteinate is present in amount of at least 0.00001%, more preferably at least 0.0001 %, even more preferably at least 0.001%, still even more preferably at least 0.01 %, and most preferably at least 0.1% by weight of the composition.

Resorcinol derivative as used herein refers to that at least one hydrogen on the ring structure and/or on a hydroxy group of the resorcinol replaced, typically with an alkyl group, and/or phenyl alkyl group. Preferably, the resorcinol derivative is 4-substituted resorcinol and more preferably the resorcinol derivative is 4-alkyl resorcinol, even more preferably the resorcinol derivative is 4-Ci to C12 alkyl resorcinol. The resorcinol derivative useful for the present invention preferably has the following formula (I): wherein each R1 and R2, independently, represents a hydrogen atom, C1-C18 alkyl group, R3 represents an alkyl group or phenyl alkyl group having from 1 to 18 carbon atoms. In a preferred embodiment, both Ri and R₂ represent hydrogen and R₃ represents an alkyl group or phenyl alkyl group having from 1 to 18 carbon atoms. More preferably, both Ri and R₂ represent hydrogen, and R₃ represents an alkyl group or phenyl alkyl group having from 2 to 12 carbon atoms.

Preferably, the resorcinol derivative comprises thiazolyl resorcinol (Thiamidol), 2- methylresorcinol, 4-chlororesorcinol, 4-methyl resorcinol, 4-ethyl resorcinol, 4-propyl resorcinol, 4-butyl resorcinol, 4-pentyl resorcinol, 4-hexyl resorcinol, 4-heptyl resorcinol, 4-octyl resorcinol, 4-nonyl resorcinol, 4-decyl resorcinol, phenylethyl resorcinol 4-acetylresorcinol, or a mixture thereof. More preferably, the resorcinol derivative comprises thiazolyl resorcinol, 2- methylresorcinol, 4-chlororesorcinol, 4-methyl resorcinol, 4-ethyl resorcinol, 4-propyl resorcinol, 4-butyl resorcinol, 4-pentyl resorcinol, 4-hexyl resorcinol, 4-heptyl resorcinol, 4-octyl resorcinol, 4-nonyl resorcinol, 4-decyl resorcinol, phenylethyl resorcinol 4-acetylresorcinol, or a mixture thereof. Even more preferably, the resorcinol derivative is selected from 4-ethyl resorcinol, 4-butyl resorcinol, 4-hexyl resorcinol, phenylethyl resorcinol, or a mixture thereof. Still even more preferably, the resorcinol derivative is selected from 4-ethyl resorcinol, 4-hexyl resorcinol or combination thereof. Most preferably resorcinol derivative is 4-hexyl resorcinol.

The amount of the resorcinol derivative is preferably in the range of 0.000001 to 8%, more preferably from 0.00001 to 4%, even more preferably from 0.0005 to 3%, still even more preferably from 0.005 to 1 %, most preferably from 0.02 to 0.5% by weight of the total amount of the composition. Preferably the amount of the 4-alkyl resorcinol is in the range of 0.000001 to 8%, more preferably from 0.00001 to 4%, even more preferably from 0.0005 to 3%, still even more preferably from 0.005 to 1%, most preferably from 0.02 to 0.5% by weight of the total amount of the composition. Preferably the amount of the 4-alkyl resorcinol is in the range of 0.000001 to 8%, more preferably from 0.00001 to 4%, even more preferably from 0.0005 to 3%, still even more preferably from 0.005 to 1%, most preferably from 0.02 to 0.5% by weight of the total amount of the composition. Preferably the amount of the total 4-ethyl resorcinol and 4-hexyl resorcinol is in the range of 0.000001 to 8%, more preferably from 0.00001 to 4%, even more preferably from 0.0005 to 3%, still even more preferably from 0.005 to 1 %, most preferably from 0.02 to 0.5% by weight of the total amount of the composition. Preferably the amount of the 4-hexyl resorcinol is in the range of 0.000001 to 8%, more preferably from 0.00001 to 4%, even more preferably from 0.0005 to 3%, still even more preferably from 0.005 to 1%, most preferably from 0.02 to 0.5% by weight of the total amount of the composition.

Preferably, the weight ratio of the carboxymethyl cysteine compound to the resorcinol derivative is 1 :40 to 1000:1 , more preferably 1 :12 to 200:1 , even more preferably 1 :3 to 50:1 , still even more preferably 1 :1 to 20:1 and most preferably 2:1 to 8:1. Preferably, the weight ratio of the carboxymethyl cysteine compound to the 4-alkyl resorcinol is 1 :40 to 1000:1 , more preferably 1 :12 to 200:1 , even more preferably 1 :3 to 50:1 , still even more preferably 1 :1 to 20:1 and most preferably 2:1 to 8:1. Preferably, the weight ratio of the carboxymethyl cysteine compound to the 4-Ci-i2 alkyl resorcinol is 1 :40 to 1000:1 , more preferably 1 :12 to 200:1 , even more preferably 1 :3 to 50:1 , still even more preferably 1 :1 to 20:1 and most preferably 2:1 to 8:1.

Preferably, the weight ratio of the lysine carboxymethyl cysteinate to the 4-alkyl resorcinol is 1 :40 to 1000:1 , more preferably 1 :12 to 200:1 , even more preferably 1 :3 to 50:1 , still even more preferably 1 :1 to 20:1 and most preferably 2:1 to 8:1. Preferably, the weight ratio of the lysine carboxymethyl cysteinate to the total amount of 4-ethyl resorcinol and 4-hexyl resorcinol is 1 :40 to 1000:1 , more preferably 1 :12 to 200:1 , even more preferably 1 :3 to 50:1 , still even more preferably 1 :1 to 20:1 and most preferably 2:1 to 8:1. Preferably, the weight ratio of the lysine carboxymethyl cysteinate to the 4-hexyl resorcinol is 1 :40 to 1000:1 , more preferably 1 :12 to 200: 1 , even more preferably 1 :3 to 50: 1 , still even more preferably 1 : 1 to 20: 1 and most preferably 2:1 to 8:1.

The composition may optionally comprise whitening pigment. Whitening pigments are typically particles of high refractive index materials. For example, the whitening pigment may have a refractive index of greater than 1.3, more preferably greater than 1.8 and most preferably from 2.0 to 2.7. Examples of such whitening pigment are those comprising bismuth oxy-chloride, boron nitride, barium sulfate, mica, silica, titanium dioxide, zirconium oxide, aluminium oxide, zinc oxide or combinations thereof. More preferred whitening pigment are particles comprising titanium dioxide, zinc oxide, zirconium oxide, mica, iron oxide or a combination thereof. Even more preferred whitening pigment are particles comprising zinc oxide, zirconium oxide, titanium dioxide or a combination thereof as these materials have especially high refractive index. Still even more preferably the whitening pigment is selected from titanium dioxide, zinc oxide or a mixture thereof and most preferred whitening pigment is titanium dioxide. The average diameter of whitening pigment is typical from 15 nm to 1 micron, more preferably from 35 nm to 800 nm, even more preferably from 50 nm to 500 nm and still even more preferably from 100 to 300 nm. Amount of whitening pigment may be 0.1 to 15%, preferably 0.5 to 5% by weight of the composition.

Preferably, the composition comprises a glutamate source selected from the group consisting of glutamine, glutamine ester, glutamic acid, pyroglutamic acid, salts, and mixtures thereof. More preferably, the composition comprises pyroglutamic acid and/or salt of pyroglutamic acid. Even more preferably, the composition comprises sodium salt of pyroglutamic acid. Preferably, the glutamate source is present in amount of 0.0001 to 10% by weight of the composition, more preferably 0.001 to 6%, even more preferably 0.01 to 3% by weight of the composition.

Preferably, the composition comprises polyhydric alcohol. Polyhydric alcohols may be selected from group of glycerin, propylyene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1 ,3-butylene glycol, isoprene glycol, ethoxylated glycerol, propoxylated glycerol or a mixture thereof. Most preferred polyhydric alcohol is glycerol known also as glycerin. The amount of polyhydric alcohol may range anywhere from 0.1 to 20%, preferably 0.5 to 15% and more preferably 2 and 10% by weight of the composition.

Preferably, the composition comprises emollient materials. Suitable emollient materials include silicones, hydrocarbons, triglycerides or a mixture thereof. These silicones may be organic, silicone-containing or fluorine-containing, volatile or non-volatile, polar or non-polar. Hydrocarbons may include mineral oil, petrolatum and polyalpha-olefins. Examples of preferred volatile hydrocarbons include polydecanes such as isododecane and isodecane (e.g. Permethyl- 99A which is available from Presperse Inc.) and the C7-C8 through C12-C15 isoparaffins (such as the Isopar Series available from Exxon Chemicals). Illustrative triglycerides but not limiting are sunflower seed oil, cotton oil, canola oil, soybean oil, castor oil, borage oil, olive oil, shea butter, jojoba oil and mixtures thereof. Mono- and di- glycerides may also be useful. Particularly preferable are glyceryl monostearate and glyceryl distearate.

Preferably, the composition comprises moisturizing agents. Particularly preferred moisturizing agents includes, petrolatum, aquaporin manipulating actives, oat kernel flour, substituted urea like hydroxyethyl urea, hyaluronic acid and/or its precursor N-acetyl glucosamine, hyaluronic acid and/or its precursor N-acetyl glucosamine, or a mixture thereof.

Some compositions may include thickeners. These may be selected from cellulosics, natural gums and acrylic polymers but not limited by this thickening agent types. Among the cellulosics are sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose and combinations thereof. Suitable gums include xanthan, pectin, karaya, agar, alginate gums and combinations thereof. Among the acrylic thickeners are homopolymers and copolymers of acrylic and methacrylic acids including carbomers such as Carbopol 1382, Carbopol 982, llltrez, Aqua SF-1 and Aqua SF-2 available from the Lubrizol Corporation. Amounts of thickener may range from 0.01 to 3% by weight of the active polymer (outside of solvent or water) in the compositions. In addition, the compositions of the invention may further include 0.5 to 10% by weight of sequestering agents, such as tetra sodium ethylenediaminetetraacetate (EDTA), EHDP or mixtures; opacifiers and pearlizers such as ethylene glycol distearate, titanium dioxide or Lytron 621 (Styrene/Acrylate copolymer); all of which are useful in enhancing the appearance or properties of the product.

The composition may comprise water in amount of 10 to 96% by weight of the composition, more preferably from 25 to 92%, even more preferably from 42 to 88%, most preferably from 55 to 82% by weight of the composition.

Preferably, the composition has a viscosity of at least 10 mPa s, more preferably in the range 30 to 10000 mPa s, even more preferably 50 to 5000 mPa s, and most preferably 100 to 2000 mPa s, when measured at 20 degrees C at a relatively high shear rate of about 20 s’¹. Preferably, the composition is in the form of fluid.

Preferably, the composition is an emulsion, more preferably an oil-in-water emulsion. Preferably the composition is a fluid liquid at 25 °C and atmospheric pressure.

Preferably, the personal care composition is a skin care composition. Skin care composition refers to a composition suitable for topical application to human skin, including leave-on and wash-off products but preferably leave-on compositions. The term “leave-on” as used with reference to compositions herein means a composition that is applied to or rubbed on the skin, and left thereon. The term “wash-off” as used with reference to compositions herein means a skin cleanser that is applied to or rubbed on the skin and rinsed off substantially immediately subsequent to application. The term "skin" as used herein includes the skin on the face, neck, chest, abdomen, back, arms, under arms, hands, and legs. Preferably “skin” means includes the skin on the face and under arms, more preferably skin means skin on the face other than lips and eyelids. The composition is particularly preferably a moisturizer rather than a make-up product.

Preferably, the composition is a topical composition. Preferably, the composition may be in the form of cream, lotion, ointment, solution, suspension, emulsion, paste, gel, powder, powder foundation, emulsion foundation, wax foundation, or spray. More preferably, the composition may be formulated in the form of cream, lotion, ointment, emulsion, gel, or a spray. Preferably the use is non-therapeutic. Preferably the method is non-therapeutic. The term non- therapeutic typically means for cosmetic purposes and not curative or therapeutic purposes.

Preferably, the composition is capable of upregulating the expression of thioredoxin reductase 1 (TXNRD1) gene by at least 1.3 fold change, more preferably 1.4 to 5 and most preferably 1.5 to 3.5 and most preferably 1.6 to 2.5 fold change, typically in comparison to personal care composition comprising neither carboxymethyl cysteine compound nor resorcinol derivative.

The following examples are provided to facilitate an understanding of the invention. The examples are not intended to limit the scope of the claims.

Examples

Materials

Example 1

This Example demonstrates the synergistic upregulation of gene expression by combining lysine carboxymethyl cysteinate and 4-hexyl resorcinol.

The normal human epidermal keratinocytes (NHEK, Lot: NHS-2021-006) (Archgene Biotechnology, Shanghai, China) were incubated in medium together with or without actives for 24 hours. After incubation, the total RNA for each NHEK was extracted using Qiagen Mini RNeasy kit (Qiagen, Cat.74106) according to manufacturer’s protocol.

The extracted RNA was quantified using Nanodrop 2000 spectrometer (Thermo Fisher Scientific, Waltham, MA, US) and reverse transcribed to generate the template cDNA using the ABScript III RT Mast Mix (Cat. BK20428, ABclonal) according to manufacturer’s protocol. Amplification of the gene encoding the TXNRD1 (Thioredoxin reductase 1) gene was performed with RT-PCR reagent (Universal SYBR Green Fast qPCR Mix kit, Cat.: RK21203, ABclonal) on the ABI Vii 7 Real-Time PCR Systems (Applied Biosystems, Thermo fisher scientific, Carlsbad, CA, USA). The Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta gene (YWHAZ) was selected as the housekeeping gene and all data on relative expression of the target genes was normalized to YWHAZ. The fold changes in expression were calculated relative to the blank control (medium having no active). All tests were conducted at least three times and Table 1 shows the fold changes in gene expression of TXNRD1.

Table 1 #: The level of the active is based on the medium. a: significantly better (p<0.05) than either of single active at same level.

As demonstrated in Table 1 , it was surprisingly found that the fold change when combining lysine carboxymethyl cysteinate and 4-hexyl resorcinol is significantly higher than the product of the fold change for lysine carboxymethyl cysteinate only and that for 4-hexyl resorcinol only. The expression of TXNRD1 gene was synergistically upregulated by combining lysine carboxymethyl cysteinate and 4-hexyl resorcinol.

Claims

1. A personal care or pharmaceutical composition comprising resorcinol derivative and carboxymethyl cysteine compound.

2. The composition according to claim 1 wherein the carboxymethyl cysteine compound comprises carboxymethyl cysteine, ester of carboxymethyl cysteine, and/or salt of carboxymethyl cysteine.

3. The composition according to claim 2 wherein the carboxymethyl cysteine compound comprises salt of carboxymethyl cysteine and preferably the carboxymethyl cysteine compound comprises lysine carboxymethyl cysteinate.

4. The composition according to any one of the preceding claims wherein the carboxymethyl cysteine compound is present in amount of at least 0.00001% and no greater than 10% by weight of the composition, preferably carboxymethyl cysteine compound is present in amount of at least 0.01% and no greater than 3% by weight of the composition.

5. The composition according to any one of the preceding claims wherein the resorcinol derivative is 4-alkyl resorcinol, preferably 4-Ci-i2 alkyl resorcinol.

6. The composition according to any one of the preceding claims wherein the amount of the resorcinol derivative is preferably in the range of 0.000001 to 8%, preferably 0.0005 to 3%, and more preferably from 0.02 to 0.5% by weight of the total amount of the composition.

7. The composition according to any one of the preceding claims wherein the resorcinol derivative is selected from 4-ethyl resorcinol, 4-hexyl resorcinol or combination thereof, more preferably the resorcinol derivative is 4-hexyl resorcinol.

8. The composition according to claim 7 wherein the amount of the 4-hexyl resorcinol is in the range of from 0.00001 to 4%, preferably from 0.02 to 0.5% by weight of the total amount of the composition.

9. The composition according to any one of the preceding claims wherein the weight ratio of the carboxymethyl cysteine compound to the resorcinol derivative is 1 :40 to 1000:1 and more preferably 2:1 to 8:1. The composition according to any one of claims 7 to 9 wherein the weight ratio of the lysine carboxymethyl cysteinate to the 4-hexyl resorcinol is 1 :40 to 1000:1 , and more preferably 1 :1 to 20:1. The composition according to any one of the preceding claims wherein the composition is an emulsion, preferably an oil-in-water emulsion. The composition according to any one of the preceding claims wherein the composition is a fluid liquid at 25 °C and atmospheric pressure. The composition according to any one of the preceding claims wherein the composition comprises water in amount of 10 to 96% by weight of the composition, preferably from 42 to 88% by weight of the composition. A method of providing antioxidation, and/or anti-aging benefit; reducing oxidative stress; and/or upregulating the expression of Thioredoxin reductase 1 gene, comprising a step of topically applying to the skin the composition of any one of the preceding claims. Use of the composition of any one of the preceding claims 1 to 12 for providing antioxidation, and/or anti-aging benefit; reducing oxidative stress; and/or upregulating the expression of thioredoxin reductase 1 gene.